Overall safety profile of avatrombopag during the randomized and extension studies
| AE category* . | Total number of subjects receiving avatrombopag (N = 64) . |
|---|---|
| ≥1 AE during treatment | 64 (100) |
| Severe (grade 3-4) AEs | 26 (41) |
| Suspected drug-related AEs† | 42 (66) |
| Serious AEs | 12 (19) |
| Serious treatment-related AEs | 4 (6) |
| Withdrawal of study drug due to AE | 10 (16) |
| Dose interruption due to AE | 8 (13) |
| Deaths | 0 |
| AE category* . | Total number of subjects receiving avatrombopag (N = 64) . |
|---|---|
| ≥1 AE during treatment | 64 (100) |
| Severe (grade 3-4) AEs | 26 (41) |
| Suspected drug-related AEs† | 42 (66) |
| Serious AEs | 12 (19) |
| Serious treatment-related AEs | 4 (6) |
| Withdrawal of study drug due to AE | 10 (16) |
| Dose interruption due to AE | 8 (13) |
| Deaths | 0 |